In quest to eliminate tropical diseases, Merck KGaA will submit anti-worming drug for approval in young children

As Merck KGaA makes moves to treat the neglected tropical disease schistosomiasis, it has announced that its treatment arpraziquantel has yielded positive Phase III trial results in children between the ages of 3 months and 6 years old, and the company will now seek regulatory approval.